Juvenile hemochromatosis - Symptoms, Causes, Treatment & Prevention

Overview

Juvenile hemochromatosis (JH) is a rare, hereditary disorder that causes the body to absorb too much iron from food, leading to iron overload in vital organs such as the heart, liver, pancreas, and endocrine glands. Unlike the more common adult‑onset hereditary hemochromatosis, JH typically presents before the age of 30 and can cause severe organ damage within a relatively short time if untreated.

• Who it affects: Most patients are diagnosed in late adolescence or early adulthood (median age 23 years). Both males and females are affected, but males often present earlier because women lose iron through menstruation and pregnancy.
• Prevalence: Juvenile hemochromatosis accounts for < 1 % of all hereditary iron‑overload cases. Estimated carrier frequency of the most common pathogenic variants (HJV, HAMP) is about 1 in 200–250 in European‑derived populations, but clinical disease is far rarer (< 1 in 100 000).^{[1] Mayo Clinic}

Symptoms

Symptoms result from iron deposition in specific organs and may be subtle at first. The list below groups them by organ system.

General

• Fatigue & weakness – due to anemia of chronic disease or cardiac involvement.
• Joint pain – especially in the knuckles and hips; often mistaken for arthritis.
• Abdominal discomfort – from hepatic enlargement.
• Skin hyperpigmentation – “bronze” coloration of the skin, especially on the face and hands.

Cardiac

• Palpitations, shortness of breath, or exercise intolerance.
• Cardiomyopathy (dilated or restrictive) leading to heart failure.
• Arrhythmias, including atrial fibrillation.

Hepatic

• Enlarged liver (hepatomegaly).
• Elevated liver enzymes (ALT, AST).
• Progressive fibrosis → cirrhosis; risk of hepatocellular carcinoma.

Endocrine & Metabolic

• Diabetes mellitus (often termed “bronze diabetes”).
• Hypogonadism – decreased libido, menstrual irregularities, infertility.
• Hypothyroidism.

Other

• Muscle cramps or myopathy.
• Arthropathy of the second and third metacarpophalangeal joints.

Because organ damage can progress quickly, any combination of these symptoms in a young adult warrants evaluation for iron overload.

Causes and Risk Factors

Juvenile hemochromatosis is autosomal recessive, meaning two defective copies of a related gene are required for disease manifestation.

Genetic Causes

• HJV (hemojuvelin) mutations – most common cause (≈ 85 % of JH cases). The p.C282Y mutation that dominates adult‑type hemochromatosis is NOT typical for JH.
• HAMP (hepcidin) mutations – rare but can produce a severe phenotype.
• TFR2 and SLC40A1 – occasionally implicated, usually with a milder course.

Risk Factors

• Having two pathogenic alleles in HJV or HAMP (inheritance from each parent).
• Consanguineous parentage increases the probability of inheriting two copies of a rare mutant allele.
• Ethnicity: most data derive from people of Northern European descent, but cases have been reported worldwide.

Environmental factors (e.g., iron‑rich diet, alcohol use) can accelerate organ injury but are not sufficient to cause JH on their own.

Diagnosis

Because symptoms overlap with many other conditions, a systematic approach is essential.

1. Clinical suspicion

• Young adult (< 30 y) with unexplained liver enzyme elevation, cardiomyopathy, or diabetes.
• Family history of early‑onset iron overload or related organ failure.

2. Laboratory studies

• Serum ferritin – often > 1 000 ng/mL (normal 20‑300). Elevated ferritin is a sensitive but not specific marker.
• Transferrin saturation (TSAT) – > 45 % (often > 80 %) is highly suggestive.
• Complete blood count, liver function panel, fasting glucose, and endocrine labs to assess organ involvement.

3. Genetic testing

Sequencing of HJV, HAMP, and other relevant genes confirms the diagnosis. Testing is recommended for the patient and, if a pathogenic variant is identified, for at‑risk family members.

4. Imaging & organ assessment

• Magnetic Resonance Imaging (MRI) with T2* – non‑invasive quantification of liver and cardiac iron concentration.
• Echocardiography – evaluates ventricular function and detects early cardiomyopathy.
• Liver ultrasound or elastography – screens for fibrosis or cirrhosis.

5. Liver biopsy (rarely needed)

Considered when MRI is unavailable or when there is suspicion of other liver disease. Histology shows iron overload (Prussian blue staining) and fibrosis.

Treatment Options

Therapy aims to remove excess iron, prevent organ damage, and manage complications.

1. Phlebotomy (Therapeutic venesection)

• First‑line for most patients without severe anemia.
• Typical regimen: 450‑500 mL of whole blood removed weekly until ferritin < 50 ng/mL, then maintenance every 2‑4 months.
• Benefits: rapid reduction of iron stores, improves cardiac and hepatic function.

2. Iron‑chelating agents

• Used when phlebotomy is contraindicated (e.g., anemia, heart failure) or as adjunct therapy.
• Deferoxamine (parenteral) – 20‑40 mg/kg/day subcutaneously.
• Deferasirox (oral) – 20‑30 mg/kg/day.
• Deferiprone (oral) – 75‑100 mg/kg/day in divided doses.
• Monitoring for renal and hepatic toxicity is essential.

3. Management of organ‑specific complications

• Cardiac: beta‑blockers, ACE inhibitors, or ARBs for heart failure; arrhythmia management per cardiology guidelines.
• Diabetes: standard antidiabetic regimen; iron reduction may improve insulin sensitivity.
• Endocrine: hormone replacement (testosterone, estrogen/progesterone) when hypogonadism is present.

4. Lifestyle & supportive measures

• Limit dietary iron (avoid fortified cereals, red meat, and iron supplements).
• Avoid vitamin C megadoses (> 500 mg/day) that increase iron absorption.
• Alcohol restriction – alcohol synergistically worsens liver injury.
• Regular exercise tailored to cardiac status.

Living with Juvenile Hemochromatosis

Adapting daily life to a chronic condition can be challenging, but structured management improves quality of life.

Monitoring schedule

• Ferritin & TSAT every 3 months during induction phase, then every 6–12 months.
• Annual cardiac MRI or echocardiogram.
• Yearly liver elastography or MRI to watch for fibrosis.
• Endocrine labs (glucose, testosterone/estradiol, thyroid) annually or as symptoms arise.

Practical tips

• Phlebotomy appointments: keep a log of dates, volume removed, and post‑procedure hemoglobin.
• Nutrition: focus on fruits, vegetables, whole grains, and low‑iron protein sources (chicken, fish). Use cooking methods that reduce iron (e.g., avoid cast‑iron cookware).
• Supplements: Avoid multivitamins containing iron or high‑dose vitamin C unless prescribed.
• Travel: Carry a medical alert card indicating JH and current treatment; bring a copy of recent labs.
• Psychosocial support: Join patient support groups (e.g., American Hemochromatosis Society) and consider counseling for chronic‑illness anxiety.

Prevention

Because JH is genetic, primary prevention is not possible, but secondary prevention reduces disease severity.

• Carrier screening: Recommended for siblings of an affected individual and for couples with a known family history.
• Genetic counseling: Provides reproductive options (prenatal testing, pre‑implantation genetic diagnosis).
• Early detection: Routine ferritin and TSAT testing for at‑risk adolescents (starting around age 10) can identify iron overload before organ damage occurs.
• Lifestyle moderation: Limiting excess dietary iron and alcohol slows progression.

Complications

If untreated, iron overload leads to irreversible organ injury.

• Cardiomyopathy & heart failure – the leading cause of death in JH patients; can progress to arrhythmias and sudden cardiac death.
• Cirrhosis – may culminate in portal hypertension, variceal bleeding, and hepatocellular carcinoma.
• Diabetes mellitus – often requires insulin; contributes to cardiovascular risk.
• Hypogonadotropic hypogonadism – infertility and reduced bone density.
• Joint arthropathy – may require orthopedic intervention.
• Skin hyperpigmentation – cosmetically distressing; improves after iron removal.

When to Seek Emergency Care

---

Sources: Mayo Clinic; Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH) – Genetics Home Reference; World Health Organization (WHO); Cleveland Clinic; European Journal of Haematology (2022); American Journal of Medicine (2021).